YB-1 protein correlates with high-risk tumor characteristics and response to high dose chemotherapy in breast cancer.

被引：0
|
作者：
Gluz, O.
Harbeck, N.
Kates, R. E.
Schmitt, M.
Mengele, K.
Royer, H-D
Eckstein, N.
Svjetlana, M.
Ting, E.
Poremba, C.
Nitz, U.
Diallo-Danebrock, R.
机构：
[1] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[2] Tech Univ, Munich, Germany
[3] Caesar Inst, Bonn, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [21] Role of dose-dense chemotherapy in high-risk early breast cancer
    Blondeaux, Eva
    Poggio, Francesca
    Del Mastro, Lucia
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (06) : 480 - 485
  • [22] Changes in circulating tumor cell counts during the course of chemotherapy in women with high-risk early breast cancer.
    Tzschaschel, Marie Lena Johanna
    Rack, Brigitte Kathrin
    Andergassen, Ulrich
    Friedl, Thomas W. P.
    Schneeweiss, Andreas
    Muller, Volkmar
    Fehm, Tanja N.
    Pantel, Klaus
    Gade, Jorg
    Lorenz, Ralf
    Rezai, Mandi
    Tesch, Hans
    Soeling, Ulrike
    Trapp, Elisabeth Katharina
    Mahner, Sven
    Schindlbeck, Christian
    Lichtenegger, Werner
    Beckmann, Matthias W.
    Fasching, Peter A.
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    Drageset, V
    Nesland, JM
    Erikstein, B
    Skovlund, E
    Sommer, H
    Anker, G
    Wist, E
    Lundgren, S
    Bergh, J
    Kvalheim, G
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (11) : 2877 - 2881
  • [24] High-dose chemotherapy with peripheral blood stem cell support for high risk breast cancer.
    Schmid, M
    Bauernhofer, T
    Resel, M
    Ploner, F
    Schippinger, W
    Gilli, R
    Lanzer, G
    Truschnig-Wilders, M
    Samonigg, H
    BONE MARROW TRANSPLANTATION, 1999, 23 : S42 - S42
  • [25] Src as a novel molecular biomarker for response to neoadjuvant chemotherapy with sequential doxorubicin and docetaxel in high-risk breast cancer.
    Minton, SE
    Munster, PN
    Cox, C
    Lacevic, M
    Lee, JH
    Beam, CA
    Muro-Cacho, CA
    Diaz, N
    Jove, R
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S53 - S54
  • [26] Gene and protein expression profile and prognosis in high-risk primary breast cancer.
    Somlo, G
    Schneider, S
    Chu, P
    Ye, W
    Frankel, P
    Ruel, C
    Doroshow, JH
    Danenberg, K
    Danenberg, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 852S - 852S
  • [27] Broad safety impact of high-dose ascorbic acid and induction chemotherapy for high-risk pancreatic cancer.
    Bruckner, Howard
    Hirschfeld, Azriel
    Gurell, Daniel
    Lee, King
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer
    Ertz-Archambault, Natalie
    Northfelt, Donald W.
    Sonbol, Mohamad Bassam
    JAMA ONCOLOGY, 2020, 6 (08) : 1299 - 1300
  • [29] SEQUENTIAL HIGH-DOSE CHEMOTHERAPY (HDCT) AND IMMUNOTHERAPY IN THE ADJUVANT TREATMENT OF HIGH-RISK BREAST CANCER
    Recchia, F.
    Saggio, G.
    Cesta, A.
    Rea, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 21 - 22
  • [30] High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
    Tallman, MS
    Gradishar, WJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (Suppl 1) : S60 - S67
12345